{"filings":[{"id":105896,"accession_number":"0001493152-26-008837","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Regen Biopharma issues 77.85M shares to settle $68,723 in debt and fees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 77,849,847 common shares between Feb 4-27, 2026 for $53,474 principal, $4,249 interest, $11,000 fees.","Shares were issued in unregistered private placement under Section 4(a)(2) with no underwriter or commission.","Post-issuance outstanding shares total 212,318,424 as of March 3, 2026.","Implied issuance price of approximately $0.0009 per share, suggesting severe dilution for existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105895,"accession_number":"0001493152-26-004733","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Regen Biopharma issues 21.4M shares in Jan 2026 for $69,550, massive dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Jan 15, 2026, issued 5,000,000 shares to satisfy $11,449 principal + $8,101 interest on convertible debt.","On Jan 29, 2026, issued 5,302,732 shares to satisfy $12,000 principal + $1,000 interest.","On Jan 30, 2026, issued 11,111,111 shares for $50,000 cash via Reg A offering.","As of Feb 2, 2026, total shares outstanding: 129,468,577; implied average issuance price ~$0.003 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105894,"accession_number":"0001493152-26-002956","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma declares 1:1 dividend of Series A Preferred stock for all share classes","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board declared dividend of one share of Series A Preferred for each share of Common, Series A, AA, M, and NC Preferred owned.","Record date is February 3, 2026; payable on or about February 9, 2026.","Dividend payable in authorized but unissued Series A Preferred stock.","All shareholders of record as of Record Date will receive the dividend on a 1:1 basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122157,"accession_number":"0001493152-25-022185","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":[],"status":"ready","headline":"Regen BioPharma issues 23.68M common shares for cash and debt conversion in Oct-Nov 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Oct 8, 2025: issued 6.8M shares for $68,000 cash.","Oct 27, 2025: issued 3.5M shares for $35,000 cash, and 4.5M shares to satisfy $30,204 debt principal plus $13,536 accrued interest.","Oct 28, 2025: issued 7.1M shares for $71,000 cash.","Nov 10, 2025: issued 1.78M shares for $17,800 cash under Tier 2 Reg A offering.","All shares sold directly by management with no underwriter or commission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122156,"accession_number":"0001493152-25-016767","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Regen BioPharma issues 40M shares to CEO and consultant for Phase I trial; shares vest on trial success","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.","Issued 20M shares to consultant Dr. Harry Lander for same purpose; same vesting condition.","Total outstanding shares jump to 79,374,704 as of Oct 3, 2025, reflecting ~100% dilution from these grants.","Phase I trial targets drug-refractory aplastic anemia using autologous stromal vascular fraction from adipose tissue.","Shares are restricted and unregistered; vest only upon successful trial completion, otherwise forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138885,"accession_number":"0001493152-25-014182","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":[],"status":"ready","headline":"Regen Biopharma raises $58.2K via unregistered sales of 5.82M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Sep 15, 2025, issued 3,320,000 shares for $33,200 to an unaffiliated investor.","On Sep 16, 2025, issued 1,000,000 shares for $10,000 to an unaffiliated investor.","On Sep 18, 2025, issued 1,500,000 shares for $15,000 to an unaffiliated investor.","All proceeds will be used for working capital; shares sold in private placements without registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138884,"accession_number":"0001641172-25-022575","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Regen Biopharma issues $100K convertible note to Labrys Fund at 60% discount conversion","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $100,000; net proceeds $85,000 after $15,000 original issue discount.","6% interest per annum; maturity date August 5, 2026.","Conversion price is 60% of lowest trading price over prior 20 trading days.","Beneficial ownership limitation set at 4.99% (can be increased to 9.99% by holder).","Shares upon conversion are unregistered and subject to restrictive legend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138883,"accession_number":"0001641172-25-021882","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Regen Biopharma enters $130K convertible note financing with CFI Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued a 6% convertible promissory note for $130,000 principal; $13,000 original issue discount, net proceeds $117,000.","Note matures July 28, 2026; interest payable in common stock at holder's option.","Conversion price set at 60% of lowest trading price over prior 20 trading days on OTC Markets.","Company reserved 15,700,485 common shares for conversion; holder must maintain 5x coverage reserve."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156364,"accession_number":"0001641172-25-014652","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Regen Biopharma issues 10M shares to CEO in settlement of $50K accrued salary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 10,000,000 common shares to CEO David R. Koos as settlement for $50,000 of accrued unpaid salary.","Shares issued under Section 4(a)(2) exempt offering; no underwriters or commissions paid.","Settlement agreement (Ex-10.1) reveals total unpaid salary of $457,113.19; only $50K settled with shares.","Post-issuance, shares outstanding increased to 31,554,704 from ~21.6M, a ~46% dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156363,"accession_number":"0001641172-25-009967","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Regen Biopharma restates FY2024 financials; prior statements not reliable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on unaudited FY2024 financials filed Nov 20, 2024; share compensation and derivative liability corrected.","Derivative liability increased by $6,816; total liabilities restated to $5.38M.","Net loss restated from $809,255 to $668,255, improvement of $198,995.","Prepaid assets reduced by $16,527; total assets restated to $161,084.","Additional paid-in capital decreased by $17,492; AOCI shows negative $204,847 from reclassification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156362,"accession_number":"0001641172-25-002908","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Regen Biopharma dismisses Bush & Associates, engages BCRG Group as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Bush and Associates CPA LLC as independent auditor effective March 31, 2025.","Engaged BCRG Group as new independent registered public accounting firm same date.","No disagreements with Bush on accounting principles or practices during engagement.","Bush only completed interim review for period ended June 30, 2024; no audit conducted.","Company requested Bush to furnish letter to SEC; no response received as of April 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191747,"accession_number":"0001493152-24-048090","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.","Net loss of $867,252; basic & diluted EPS of ($0.21) on 4.1M weighted avg shares.","Cash and cash equivalents at Sept 30, 2024: just $716; total assets $177,611.","Total liabilities $5.37M vs. stockholders deficit ($5.19M); accumulated deficit $20.6M.","Company remains development-stage; no FDA approvals for any product candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":236560.0,"consensus_period":"2024-09-30","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208221,"accession_number":"0001493152-24-037011","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Regen Biopharma declares 1-for-1 stock dividend payable Nov 1","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of one common share for each share of common and Series A, AA, M, NC preferred stock held.","Record date is October 17, 2024; payment on or about November 1, 2024.","Shares will come from authorized but unissued common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208220,"accession_number":"0001493152-24-036161","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Regen Biopharma issues $250K promissory note to Coventry; $25K OID, convertible on default","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $250K; original issue discount $25K, net proceeds $200K.","10% annual interest; ten monthly payments of $27,500 starting Nov 4, 2024, due Sept 4, 2025.","Upon event of default, note converts to common stock at 90% of lowest 20-day trading price before conversion.","Company issued 500K commitment shares; 350K to be returned to treasury if no default occurs.","$152K of proceeds used to repay existing principal and interest to Coventry from a prior note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225808,"accession_number":"0001607062-24-000219","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Regen Biopharma appoints Bush and Associates CPA as new independent auditor effective May 28, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee approved engagement of Bush and Associates CPA LLC as independent auditor on May 28, 2024.","Filing does not disclose previous auditor or reasons for change.","Effective date of engagement is May 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225807,"accession_number":"0001607062-24-000211","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Regen Biopharma declares Series A Preferred stock dividend and amends charter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 20, 2024, amended Certificate of Incorporation to allow share dividends between classes/series.","Board declared a dividend of 2 shares of Series A Preferred for each share of Common, Series A, AA, M, NC Preferred owned.","Record date: June 20, 2024; payment date: on or about July 1, 2024.","No ticker provided; company is an emerging growth company with no securities registered under Section 12(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225806,"accession_number":"0001607062-24-000175","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Regen Biopharma dismisses auditor BF Borgers due to SEC cease-and-desist order","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BF Borgers CPA PC dismissed as independent auditor effective May 10, 2024, following SEC order of May 3, 2024.","SEC order instituted administrative and cease-and-desist proceedings against BF Borgers and its sole partner.","No disagreements or reportable events occurred with BF Borgers during fiscal years 2022 and 2023.","Company will need to engage a new independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225805,"accession_number":"0001607062-24-000150","cik":1589150,"company_name":"Regen BioPharma Inc","ticker":"RGBP","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01","8.01","3.02","9.01"],"status":"ready","headline":"Regen Biopharma issues 20,068 Series A Preferred shares for consulting; amends sublease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 20,068 Series A Preferred shares to Value Quest Inc. for one-year social media consulting services.","Consulting covers Facebook and Twitter management; shares are unregistered restricted securities.","Amended sublease with BST Partners (controlled by CEO David Koos) to reimburse shared expenses in addition to $5k/month base rent.","Subtenant also required to pay shared expenses retroactive to January 1, 2024, per amendment.","Both transactions involve related party: David Koos is CEO and also controls BST Partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":181744.61666666667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}